Table 2.
Characteristics of four patients with infective endocarditis by Pseudomonas mendocina: antimicrobial resistance, treatment and outcomes. Values show cases among patients with available data.
| Characteristic | Value |
|---|---|
| Male, n (%) | 3 out of 4 (75%) |
| Age, mean (+/− SD) in years | 46 (16.7) |
| Medical History | |
| Previous cardiac surgery, n (%) | 2 out of 4 (50%) |
| Prosthetic cardiac valve, n (%) | 1 out of 4 (25%) |
| No known predisposing factors, n (%) | 3 out of 4 (75%) |
| Concomitant bacteremia, n (%) | 4 out of 4 (100%) |
| Data on Infection | |
| Duration of symptoms, median (IQR) in days | 7 (5–45) |
| Patients with fever, n (%) | 4 out of 4 (100%) |
| Patients with sepsis, n (%) | 2 out of 3 (66.7%) |
| Antimicrobial Resistance | |
| Ampicillin resistance, n (%) | 3 out of 4 (75%) |
| Aminoglycoside resistance, n (%) | 0 out of 4 (0%) |
| Third or fourth generation cephalosporin resistance, n (%) | 0 out of 3 (0%) |
| Piperacillin–tazobactam resistance, n (%) | 0 out of 3 (0%) |
| Quinolone resistance, n (%) | 0 out of 3 (10) |
| Carbapenem resistance, n (%) | 0 out of 2 (0%) |
| Co-trimoxazole resistance, n (%) | 0 out of 1 (0%) |
| Colistin resistance, n (%) | 0 out of 1 (0%) |
| Treatment of P. mendocina Infections | |
| Third or fourth generation cephalosporin, n (%) | 2 out of 4 (50%) |
| Quinolones, n (%) | 2 out of 4 (50%) |
| Aminoglycoside, n (%) | 2 out of 4 (50%) |
| Piperacillin–tazobactam, n (%) | 1 out of 4 (25%) |
| Carbapenems, n (%) | 1 out of 4 (25%) |
| Surgical management, n (%) | 2 out of 4 (50%) |
| Duration of treatment, median (IQR) in days | 49 (42–82.3) |
| Outcome | |
| Clinical cure, n (%) | 4 out of 4 (100%) |
| Deaths due to the infection, n (%) | 0 out of 4 (0%) |
| Deaths overall, n (%) | 0 out of 4 (0%) |
SD: standard deviation; IQR: intraquartile range.